Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has promoted Patrick Cushing, Ph.D., to Vice President, Operations of Rentschler Biopharma, Inc., the company’s U.S. subsidiary.
 
In this newly created position, Cushing will oversee and manage all operational processes at the site and report to Rentschler Biopharma’s Chief Operating Officer, Christiane Bardroff.
 
“The appointment of Patrick Cushing to Vice President Operations at our state-of-the-art manufacturing site in Milford reflects our commitment to delivering the highest quality services to our clients,” said Bardroff. “His unwavering dedication aligns perfectly with our vision of advancing medicine to save lives.”
 
Cushing remarked: “I am excited to take on this new role as we significantly expand our capacity in the U.S. At Rentschler Biopharma, we are truly one team. In my new role, I am particularly looking forward to leveraging synergies with our global organization to further streamline the development and increase the agility with which we bring new medicines to market. I am confident in our team’s ability to make a positive difference in the lives of patients worldwide, and I am honored to be part of this impactful journey.”

About Dr. Patrick Cushing

Cushing joined Rentschler Biopharma in 2021 and has served as Senior Director of Manufacturing Operations at the company’s site in Milford, MA. With over a decade of experience in structure-based drug discovery and large molecule process development, Cushing has been instrumental in enhancing Chemistry, Manufacturing, and Controls (CMC) processes.
 
His expertise spans the development of diverse molecules, from plasmid DNA to recombinant proteins, including complex biologics such as challenging proteins, bispecific antibodies, enzymes, and protein complexes.